 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--- GRPH GraphiteBio--Graphite Bio, Inc. Nasdaq: GRPH, a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the closing of its previously announced initial public offering of 14,000,000 shares of its common stock at a price to the public of 17.00 per share on June 29, 2021. In addition, on June 29, 2021, the underwriters exercised in full their option to pu 